Navigation Links
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
Date:2/4/2013

ath to registration and, pending additional positive data from the ongoing study, will make decisions on future study designs in 2013.

ARRY-797 – Data presented at ACR meeting, biomarkers suggest disease state modification potentialArray gave a "late-breaker" presentation at the 2012 American College of Rheumatology Annual Meeting.  The presentation included data on ARRY-797's analgesic effect and markers of disease modification.  In addition, biomarkers of cartilage (COMP) and bone (CTX‑I) degradation were assessed. ARRY‑797 treatment resulted in statistically significant decreases in COMP and CTX‑I at week 4 (decreases of 10% and 38% versus placebo, respectively). The decrease in CTX‑I was sustained and returned to baseline by the follow‑up visit.  Further evaluation of the potential for disease modifying activity is warranted. 

Array announced in July 2012 that treatment with ARRY-797, a non-opioid, resulted in a statistically significant reduction in pain over a 28-day period compared to placebo, as measured using the Western Ontario and McMaster Universities Arthritis Index (WOMAC®) pain subscale (a 0 – 10 numerical pain rating scale), in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).  ARRY-797 is a novel, oral, selective inhibitor with a mechanism of action unique from that of currently approved pain medications.  Given our internal focus on hematology/oncology, Array is seeking a partnership to maximize the value of this drug.

MEK-162 – Phase 3 pivotal trial announced and posted by NovartisAt its R&D Investor event in November 2012, Novartis indicated that it intends to initiate a Phase 3 pivotal trial for MEK-162 in patients with NRAS mutant mela
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
11. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)...  The Council for Entrepreneurial Development (CED), the ... country, today released a mid-year update to its ... It showed that in the first half of ... in the technology, life science, advanced manufacturing and ... variety of sources. Significant investment in technology companies and ...
(Date:9/16/2014)... September 16, 2014 Convoy Therapeutics, ... and effective products to treat patients directly at ... a proprietary SPACE™ Technology Platform announced today that ... will present at the White Hat Life Science ... Hyatt Regency Phoenix. In addition, interested individuals ...
(Date:9/16/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive interim results ... evaluate once-weekly TransCon Growth Hormone in children with ... results will be presented at the 7th International ... held October 15-18, 2014, in Singapore.  ...
(Date:9/16/2014)... 16, 2014 According to Jeff Howell, ... of ITRA Global, new development in Downtown Toronto is ... council approving another 755 storeys of new development last ... cranes will be dominating the Toronto skyline for the ... an unquenchable thirst for new development. , As the ...
Breaking Biology Technology:CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3
... ... and Roles , ... Canberra, Australia (Vocus) October 27, 2009 -- Global food security, which is increasingly being ... and executed public and private partnerships, William S. Niebur , vice president – ...
... Oct. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ... that it has been granted its 33rd U.S. ... Resistant Neoplastic Cells With a Virus." The patent ... with currently approved chemotherapeutic agents to treat patients ...
... Oct. 27 Precision Antibody(TM) has been selected ... National Cancer Institute (NCI),s Clinical Proteomic Technologies for Cancer ... standardizing the quality of monoclonal antibody reagents available for ... result of a third solicitation for contract proposals from ...
Cached Biology Technology:Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 2Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 3Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3
(Date:9/16/2014)... 2014)The North American Menopause Society (NAMS) has published ... of midlife womenon everything from hot flashes to ... Menopause Society Recommendations for Clinical Care of Midlife ... journal Menopause . This is the first, ... of midlife women freely available to all clinicians ...
(Date:9/16/2014)... September 13, 2014. The fire is human-caused and ... acres in size and is mostly being fueled by ... Monday night due to higher humidity. Yesterday (8/15), ... to construct a fireline on the West and North sides ... the fire: , 7 20-person Crews, 4 Hot Shot Crews, ...
(Date:9/16/2014)... has its own bacterial identity. That,s the conclusion of ... who studied the genetic fingerprints of bacteria on 57 ... "This study demonstrates for the first time that host ... strategies possess very different microbial communities on their leaves," ... researcher in the UO,s Institute of Ecology and Evolution ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2
... of Leicester have identified for the first time a new ... in our blood following a meal. They have ... to maintain correct blood sugar levels. The breakthrough was ... by Professor Andrew Tobin, Professor of Cell Biology, who is ...
... of many countries in Europe and Asia. Great Tits ... long been known individuals vary considerably in their willingness to ... or "proactive" are quick explorers and are comparatively aggressive, ... differences are at least in part genetically determined and as ...
... be able to receive more effective, personalized treatments for ... cancer biology, experts will say at the Cancer Biology ... Medical Oncology (ESMO) in Nice this week. ... transformation, governments, pharmaceutical companies and doctors urgently need to ...
Cached Biology News:Bird-brained? Birds' personalities are correlated with their hormone levels 2New strategies for cancer drug development urgently needed 2New strategies for cancer drug development urgently needed 3
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
... SuperScript™ II RNase H- Reverse Transcriptase ... SuperScript™ RNase H- RT. It is a ... strand from single-stranded RNA DNA or an ... by the introduction of point mutations rather ...
... Array CGH Genomic Labeling Systems are a ... of genomic DNA samples for array-based Comparative ... and direct labeling formats, the BioPrime Plus ... flexible solution to your genomic labeling needs. ...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Biology Products: